Morgan Stanley
ARDS

Morgan Stanley’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Morgan Stanley’s Portfolio ARDS Stock Details ARDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,275
Closed -$2K – 8122
2022
Q1 		$2K Buy
+1,275
New +$2.41K ﹤0.01% 7791
2021
Q2 		– Sell
-500
Closed -$3K – 7846
2021
Q1 		$3K Buy
+500
New +$3.38K ﹤0.01% 7234
2019
Q4 		– Sell
-229
Closed -$2K – 6829
2019
Q3 		$2K Buy
+229
New +$2.1K ﹤0.01% 6502

Other funds holding ARDS

Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MWM
Minot Wealth Management Westwood, Massachusetts $389M AUM 3.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley's ARDS Position: Q2 2022 in Review

Morgan Stanley sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q2 2022, closing a stake of 1,275 shares — an estimated $2K sold.

Morgan Stanley first reported a position in ARDS in Q3 2019 and held it in 3 quarters. The position peaked at $3K in Q1 2021. 19 funds tracked by Wall St. Rank hold ARDS as of Q2 2022.

  • Morgan Stanley reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Morgan Stanley sold 1,275 Aridis Pharmaceuticals Inc. Common Stock shares in Q2 2022, an estimated $2K.
  • Morgan Stanley first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q3 2019 and held it in 3 quarters.
  • Morgan Stanley's Aridis Pharmaceuticals Inc. Common Stock position peaked at $3K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q2 2022.

Based on Morgan Stanley's 13F filing for Q2 2022, filed 15 Aug 2022.